# TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

> **NCT03032484** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 25 (actual)

## Conditions studied

- Astrocytoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** TVB-2640

## Key facts

- **NCT ID:** NCT03032484
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-18
- **Primary completion:** 2020-04-04
- **Final completion:** 2021-04-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03032484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03032484, "TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03032484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*